Laboratorios Richmond SACIF

Laboratorios Richmond SACIF Gross Margin

The Gross Margin of Laboratorios Richmond SACIF (RICH.BA) as of Nov 22, 2026 is 54.49 %. In the previous year, Gross Margin was 52.66 % — a change of 3.48% (higher).

Gross Margin

54.49 %

YoY

3.48%

Last updated:

Gross Margin of Laboratorios Richmond SACIF is 2024 54.49 % . Gross Margin of Laboratorios Richmond SACIF was 2023 52.66 % . It decreases by 3.48% higher compared to the previous year.

For Laboratorios Richmond SACIF, the gross margin of 54.5% is up versus 48.7% a few years ago.

The Laboratorios Richmond SACIF Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2017
49.29 ARS
Jan 1, 2018
44.30 ARS
Jan 1, 2019
48.55 ARS
Jan 1, 2020
48.73 ARS
Jan 1, 2021
29.67 ARS
Jan 1, 2022
47.26 ARS
Jan 1, 2023
52.66 ARS
Jan 1, 2024
54.49 ARS
The Laboratorios Richmond SACIF Gross Margin history
YEARGross MarginYoY
54.49 %+3.48%
52.66 %+11.42%
47.26 %+59.33%
29.67 %-39.13%
48.73 %+0.38%
48.55 %+9.59%
44.30 %-10.12%
49.29 %-10.91%
55.33 %-0.16%
55.42 %+12.98%
49.05 %+10,173.46%
0.48 %+9.50%
0.44 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Laboratorios Richmond SACIF Stock analysis

What does Laboratorios Richmond SACIF do? Laboratorios Richmond SACIF is a specialized pharmaceutical company focused on the manufacturing and marketing of medications. It was founded in 1935 and is headquartered in Buenos Aires, Argentina. The company has extensive experience in the development of medications and biological products, with expertise in pharmaceutical research and development. It has various business divisions including generics, biological medications, vaccines, oncology medications, and medical devices. The company's products range from simple painkillers and antihistamines to important medications for treating cancer and HIV. Richmond SACIF also manufactures vaccines against diseases such as Hepatitis A and B, polio, influenza, tetanus, and other infectious diseases. Additionally, the company produces a wide range of medications for treating different types of cancer and offers medical instruments and surgical devices. Its business model focuses on innovation and meeting the needs of patients, investing in research and development to develop new and innovative products. The company also has strict quality control measures to ensure the highest pharmaceutical standards. With its rich history and broad range of products, Laboratorios Richmond SACIF is a key player in the global pharmaceutical market and will continue to play an important role in improving the health of people worldwide. Laboratorios Richmond SACIF is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Laboratorios Richmond SACIF stock

Gross Margin of Laboratorios Richmond SACIF is 54.49 % in 2024.

Gross Margin of Laboratorios Richmond SACIF changed from 52.66 % to 54.49 %, representing a 3.48% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Laboratorios Richmond SACIF since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Laboratorios Richmond SACIF with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Laboratorios Richmond SACIF

All Key Metrics — Laboratorios Richmond SACIF